Expression of HIF-1α, VEGF and EPO in peripheral blood from patients with two cardiac abnormalities associated with hypoxia

Clinical Biochemistry

Volumn 43, Issue 3, 2010, Pages 234-239

  Lemus Varela, M L ^a   Flores Soto, M E ^b   Cervantes Munguia R ^a   Torres Mendoza, B M G ^c   Gudino Cabrera G ^d   Chaparro Huerta, V ^b   Ortuno Sahagun D ^d   Beas Zarate C ^b,d  

^a Hospital de Pediatría UMAE   (Mexico)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d Departamento de Biología Celular y Molecular   (Mexico)

Author keywords

Cyanotic congenital heart disease; EPO; Hypoxemia; Hypoxia inducible factor 1 alpha; Persistent pulmonary hypertension; VEGF

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; VASCULOTROPIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYANOTIC HEART DISEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE; NEWBORN; NEWBORN HYPOXIA; NUCLEOTIDE SEQUENCE; PERSISTENT PULMONARY HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANOXIA; ERYTHROPOIETIN; HEART DISEASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFANT; INFANT, NEWBORN; PERSISTENT FETAL CIRCULATION SYNDROME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 74449085743     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.09.022     Document Type: Article

References (38)

1. Semenza G.L. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J. Lab. Clin. Med. 131 (1998) 207-214
2. Rajatapiti P., van der Horst I.W., de Rooij J.D., et al. Expression of hypoxia-inducible factors in normal human lung development. Pediatr. Dev. Pathol. 11 3 (2008) 193-199
3. Ostrea E.M., Villanueva-Uy E.T., Natarajan G., and Uy H.G. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management. Paediatr. Drugs 8 3 (2006) 179-188
4. Latini G., Del Vecchio A., De Felice C., Verrotti A., and Bossone E. Persistent pulmonary hypertension of the newborn: therapeutical approach. Mini. Rev. Med. Chem. 8 14 (2008) 1507-1513
5. Ho JJ, Rasa G.. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database of Systematic Reviews 2007, (3). Art. No.: CD005588. DOI: 10.1002/14651858.CD005588.pub2.
6. Angus D.C., Linde-Swirble W.T., Clermont G., Griffin M.F., and Clark R.H. Epidemiology of neonatal respiratory failure in the United States. Am. J. Resp. Crit. Care Med. 164 (2001) 1154-1160
7. Kallén B., and Otterbland P. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Safety 17 (2008) 801-806
8. Hernández-Díaz S., Van Marter L.J., Werler M.M., Louik C., and Mitchell A.A. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 120 2 (2007) e272-82
9. Hoffman J.I., and Kaplan S. The incidence of congenital heart disease. J. Am. Coll. Cardiol. 39 12 (2002) 1890-1900
10. Chang R.K., Gurvitz M., and Rodriguez S. Missed diagnosis of critical congenital heart disease. Arch. Pediatr. Adolesc. Med. 162 10 (2008) 969-974
11. Minet E., Michel G., Mottet D., Raes M., and Michiels C. Transduction pathways involved in hypoxia-inducible factor-1 phosphorylation and activation. Free Radic. Biol. Med. 31 (2001) 847-855
12. Huang L.E., and Bunn H.F. Hypoxia-inducible factor and its biomedical relevance. J. Biol. Chem. 278 (2003) 19575-19578
13. Seta K.A., and Millhorn D.E. Functional genomics approach to hypoxia signaling. J. Appl. Physiol. 96 (2004) 765-773
14. 2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J. Appl. Physiol. 96 (2004) 1173-1177
15. Zhang B., Tanaka J., Yang L., et al. Protective effect of vitamin E against focal brain ischemia and neuronal death through induction of target genes of hypoxia-inducible factor 1. Neuroscience 126 (2004) 433-440
16. Agani F.H., Pichiule P., Chavez J.C., and LaManna J.C. The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. J. Biol. Chem. 275 (2000) 35863-35867
17. Bergeron M., Gidday J.M., Yu A.Y., Semenza G.L., Ferriero D.M., and Sharp F.R. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann. Neurol. 48 (2000) 285-296
18. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13 (2001) 167-171
19. Lee J.W., Bae S.H., Jeong J.W., Kim S.H., and Kim K.W. Hypoxia-inducible factor (HIF-1) α: its protein stability and biological functions. Exp. Mol. Med. 36 (2004) 1-12
20. Jones K.L., Krous H.F., Nadeau J., Blackbourne B., Zielke H.R., and Gozal D. Vascular endothelial growth factor in the cerebrospinal fluid of infants who died of sudden infant death syndrome: evidence for antecedent hypoxia. Pediatrics 111 (2003) 358-363
21. Sola A., Rogido M., Lee B.H., Genetta T., and Wen T.C.h. Erythropoietin alter focal cerebral ischemia activates the janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr. Res. 57 (2005) 481-487
22. Shah P.S., and Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst. Rev. 18 3 (2007) CD005494
23. Peterson A.L., Deatsman S., Frommelt M.A., Mussatto K., and Frommelt P.C. Correlation of echocardiographic markers and therapy in persistent pulmonary hypertension of the newborn. Pediatr. Cardiol. 30 2 (2009) 160-165
24. Tipoe G.L., Lau T.Y., Nanji A.A., and Fung M.L. Expression and functions of vasoactive substances regulated by hypoxia-inducible factor-1 in chronic hypoxemia. Cardiovasc. Hematol. Agents Med. Chem. 4 (2006) 199-218
25. Kasuno K, Takabuchi S, Fukuda K, et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem 2004;279(4):2550-8.
26. Starnes S.L., Duncan B.W., Kneebone J.M., et al. Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease. J. Thorac. Cardiovasc. Surg. 119 3 (2000) 534-539
27. Quing M., Gorlach A., Schumacher K., et al. The hypoxia-inducible factor HIF-1 promotes intramyocardial expression of VEGF in infants with congenital cardiac defects. Basic Res. Cardiol. 102 (2007) 224-232
28. Ootaki Y., Yamaguchi M., Yoshimura N., Oka S., Yoshida M., and Hasegawa T. Vascular endothelial growth factor in children with congenital heart disease. Ann. Thorac. Surg. 75 5 (2003) 1523-1526
29. Li Q.F., and Dai A.G. Hypoxia-inducible factor-1 alpha regulates the role of vascular endothelial growth factor on pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Chin. Med. J. (Engl). 117 (2004) 1023-1028
30. Nadeau S., Baribeau J., Janvier A., and Perreault T. Changes in expression of vascular endothelial growth factor and its receptors in neonatal hypoxia-induced pulmonary hypertension. Pediatr. Res. 58 (2005) 199-205
31. Arjamaa O., and Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp. Eye Res. 83 (2006) 473-483
32. Fung M.L. Hypoxia-inducible factor-1: a molecular hint of physiological changes in the carotid body during long-term hypoxemia?. Curr. Drug Targets Cardiovasc. Haematol. Disord. 3 (2003) 254-259
33. Papaioannou A.I., Kostikas K., Kollia P., and Gourgoulianis K.I. Clinical implications for vascular endothelial growth factor in the lung: friend or foe?. Respir. Res. 7 (2006) 128
34. Kaur C., Sivakumar V., Ang L.S., and Sundaresan A. Hypoxic damage to the periventricular white matter in neonatal brain: role of vascular endothelial growth factor, nitric oxide and excitotoxicity. J. Neurochem. 98 (2006) 1200-1216
35. Narasimhan P., Liu J., Song Y.S., Massengale J.L., and Chan P.H. VEGF stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endothelial cells after ischemic conditions. Stroke 40 4 (2009) 1467-1473
36. Taoufik E., Petit E., Divoux D., et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc. Natl. Acad. Sci. U. S. A. 105 16 (2008) 6185-6190
37. Fletcher L., Kohli S., Sprague S.M., et al. Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. J. Neurosurg. 111 1 (2009) 164-170
38. Pialoux V., Mounier R., Brown A.D., Steinback G.D., Rawling J.M., and Poulin M.J. Relationship between oxidative stress and HIF-1α mRNA during sustained hypoxia in humans. Free Radic. Biol. Med. 46 (2009) 321-326